FDA Draft Guidance: Hematologic Malignancy and Oncologic Disease: Considerations for Use of Placebos and Blinding in Randomized Controlled Clinical Trials for Drug Product Development Guidance for Industry

FDA Draft Guidance: Hematologic Malignancy and Oncologic Disease: Considerations for Use of Placebos and Blinding in Randomized Controlled Clinical Trials for Drug Product Development Guidance for Industry: https://ift.tt/2wh9vlq Read more... https://ift.tt/2NkT7Xt